Europe
Galapagos NV will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.
Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN®for active immunization against smallpox in adults age 18 years and older.
Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim.
Turning an existing partner into a wholly owned subsidiary, Novartis is acquiring CellforCure from biotechnology group LFB for an undisclosed figure.
NOXXON Pharma N.V. announced today that the company will participate in the East/West CEO Forum – an invite-only event that brings together the global leaders of the biopharma community.
Epigenomics AG today announced the initiation of a multi-center validation and development study of its methylated cell free DNA biomarkers to aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.
Favorable safety and statistically significant efficacy of oral ABX464 demonstrated in a completed randomized, double-blind, placebo-controlled induction trial based on clinical and endoscopic endpoints
Researchers at the University of Eastern Finland have discovered new changes occurring in the human brain in the early stages of Alzheimer’s disease.
Study will be conducted at up to 20 leading transplant centers in the U.S.
PRESS RELEASES